Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27,111 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lithiation Induced Phases in 1T'-MoTe2 Nanoflakes.
Xu S, Evans-Lutterodt K, Li S, Williams NL, Hou B, Huang JJ, Boebinger MG, Lee S, Wang M, Singer A, Guo P, Qiu DY, Cha JJ. Xu S, et al. ACS Nano. 2024 Jul 2;18(26):17349-17358. doi: 10.1021/acsnano.4c06330. Epub 2024 Jun 18. ACS Nano. 2024. PMID: 38889099
Real-space visualization of a defect-mediated charge density wave transition.
Hart JL, Pan H, Siddique S, Schnitzer N, Mallayya K, Xu S, Kourkoutis LF, Kim EA, Cha JJ. Hart JL, et al. Among authors: xu s. Proc Natl Acad Sci U S A. 2024 Aug 13;121(33):e2402129121. doi: 10.1073/pnas.2402129121. Epub 2024 Aug 6. Proc Natl Acad Sci U S A. 2024. PMID: 39106309
FcRn-guided antigen trafficking enhances cancer vaccine efficacy.
Hong M, Liu M, Zhu F, Zhao D, Liu G, Han T, Fei C, Zeng W, Chen S, Wu Q, Li B, Wu S, Shang Y, Ma H, Zhou S, Xu S, Jin T. Hong M, et al. Among authors: xu s. Cancer Immunol Immunother. 2025 Jan 3;74(2):54. doi: 10.1007/s00262-024-03888-y. Cancer Immunol Immunother. 2025. PMID: 39751965
Metastatic sites of baseline as predictors in recurrent or metastatic nasopharyngeal carinoma treated with PD-L1 inhibitor: a secondary analysis of multicenter, single-arm, phase II study (KL-A167).
Li Y, Min Y, Wei Z, Liu Z, Pei Y, Yang Y, Gao K, Song G, Xu S, He S, Ge J, Qing Y, Wei Y, Ai P, Chen Y, Peng X. Li Y, et al. Among authors: xu s. Cancer Immunol Immunother. 2025 Jan 3;74(2):72. doi: 10.1007/s00262-024-03905-0. Cancer Immunol Immunother. 2025. PMID: 39751901 Clinical Trial.
27,111 results
You have reached the last available page of results. Please see the User Guide for more information.